Loading…
NEIL3 may act as a potential prognostic biomarker for lung adenocarcinoma
Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death. This study aimed to develop and validate reliable prognostic biomarkers and signature. Differentially expressed genes were identified based on three Gene Expression Omnibus (GEO) datasets. Based on 1052 samples' data from...
Saved in:
| Published in: | Cancer cell international 2021-04, Vol.21 (1), p.228-228, Article 228 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c597t-319977871a6941f172e944dc79091bfe3903d588005e94ba6a5a8abc2c75885f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c597t-319977871a6941f172e944dc79091bfe3903d588005e94ba6a5a8abc2c75885f3 |
| container_end_page | 228 |
| container_issue | 1 |
| container_start_page | 228 |
| container_title | Cancer cell international |
| container_volume | 21 |
| creator | Zhao, Cui Liu, Jian Zhou, Haomiao Qian, Xin Sun, Hui Chen, Xuewen Zheng, Miaosen Bian, Tingting Liu, Lei Liu, Yifei Zhang, Jianguo |
| description | Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death. This study aimed to develop and validate reliable prognostic biomarkers and signature.
Differentially expressed genes were identified based on three Gene Expression Omnibus (GEO) datasets. Based on 1052 samples' data from our cohort, GEO and The Cancer Genome Atlas, we explored the relationship of clinicopathological features and NEIL3 expression to determine clinical effect of NEIL3 in LUAD. Western blotting (22 pairs of tumor and normal tissues), Real-time quantitative PCR (19 pairs of tumor and normal tissues), and immunohistochemical analyses (406-tumor tissues subjected to microarray) were conducted. TIMER and ImmuCellAI analyzed relationship between NEIL3 expression and the abundance of tumor-infiltrating immune cells in LUAD. The co-expressed-gene prognostic signature was established based on the Cox regression analysis.
This study identified 502 common differentially expressed genes and confirmed that NEIL3 was significantly overexpressed in LUAD samples (P |
| doi_str_mv | 10.1186/s12935-021-01938-4 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cdbc26d62c684a5587210dafff0425e4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cdbc26d62c684a5587210dafff0425e4</doaj_id><sourcerecordid>2516223670</sourcerecordid><originalsourceid>FETCH-LOGICAL-c597t-319977871a6941f172e944dc79091bfe3903d588005e94ba6a5a8abc2c75885f3</originalsourceid><addsrcrecordid>eNpdkU9v1DAQxS0EoqXwBTggS1y4hHrs-N8FCVUFVlqVS3u2Jo69ZMnGi51U6rfH2y1Vy8nWzJuf3swj5D2wzwBGnRfgVsiGcWgYWGGa9gU5hVbLhhulXz75n5A3pWwZA20Ue01OhDDagpKnZHV1uVoLusM7in6mWCjSfZrDNA840n1OmymVefC0G9IO8--QaUyZjsu0odiHKXnMfphq7y15FXEs4d3De0Zuvl1eX_xo1j-_ry6-rhsvrZ4bAdZqbTSgsi1E0DzYtu29tsxCF4OwTPTSGMZkbXSoUKLBznOva1VGcUZWR26fcOv2eai27lzCwd0XUt44zNXxGJzv65zqFffKtCil0RxYjzFG1nIZ2sr6cmTtl24Xel_Xzjg-gz7vTMMvt0m3zjBpwRwAnx4AOf1ZQpndbig-jCNOIS3FcQmKc6E0q9KP_0m3aclTPVVVcVPjYEpWFT-qfE6l5BAfzQBzh9TdMXVXU3f3qbuDiw9P13gc-Rez-AsydabG</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528916065</pqid></control><display><type>article</type><title>NEIL3 may act as a potential prognostic biomarker for lung adenocarcinoma</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Zhao, Cui ; Liu, Jian ; Zhou, Haomiao ; Qian, Xin ; Sun, Hui ; Chen, Xuewen ; Zheng, Miaosen ; Bian, Tingting ; Liu, Lei ; Liu, Yifei ; Zhang, Jianguo</creator><creatorcontrib>Zhao, Cui ; Liu, Jian ; Zhou, Haomiao ; Qian, Xin ; Sun, Hui ; Chen, Xuewen ; Zheng, Miaosen ; Bian, Tingting ; Liu, Lei ; Liu, Yifei ; Zhang, Jianguo</creatorcontrib><description>Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death. This study aimed to develop and validate reliable prognostic biomarkers and signature.
Differentially expressed genes were identified based on three Gene Expression Omnibus (GEO) datasets. Based on 1052 samples' data from our cohort, GEO and The Cancer Genome Atlas, we explored the relationship of clinicopathological features and NEIL3 expression to determine clinical effect of NEIL3 in LUAD. Western blotting (22 pairs of tumor and normal tissues), Real-time quantitative PCR (19 pairs of tumor and normal tissues), and immunohistochemical analyses (406-tumor tissues subjected to microarray) were conducted. TIMER and ImmuCellAI analyzed relationship between NEIL3 expression and the abundance of tumor-infiltrating immune cells in LUAD. The co-expressed-gene prognostic signature was established based on the Cox regression analysis.
This study identified 502 common differentially expressed genes and confirmed that NEIL3 was significantly overexpressed in LUAD samples (P < 0.001). Increased NEIL3 expression was related to advanced stage, larger tumor size and poor overall survival (p < 0.001) in three LUAD cohorts. The proportions of natural T regulatory cells and induced T regulatory cells increased in the high NEIL3 group, whereas those of B cells, Th17 cells and dendritic cells decreased. Gene set enrichment analysis indicated that NEIL3 may activate cell cycle progression and P53 signaling pathway, leading to poor outcomes. We identified nine prognosis-associated hub genes among 370 genes co-expressed with NEIL3. A 10-gene prognostic signature including NEIL3 and nine key co-expressed genes was constructed. Higher risk-score was correlated with more advanced stage, larger tumor size and worse outcome (p < 0.05). Finally, the signature was verified in test cohort (GSE50081) with superior diagnostic accuracy.
This study suggested that NEIL3 has the potential to be an immune-related therapeutic target and an independent predictor of LUAD prognosis. We also developed a prognostic signature for LUAD with a precise diagnostic accuracy.</description><identifier>ISSN: 1475-2867</identifier><identifier>EISSN: 1475-2867</identifier><identifier>DOI: 10.1186/s12935-021-01938-4</identifier><identifier>PMID: 33879165</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Adenocarcinoma ; Bioinformatics ; Biomarkers ; Cell cycle ; Dendritic cells ; DNA microarrays ; Gene expression ; Gene set enrichment analysis ; Genomes ; Helper cells ; Immunohistochemistry ; Immunoregulation ; Lung adenocarcinoma ; Lung cancer ; Lymphatic system ; Lymphocytes B ; Lymphocytes T ; Medical prognosis ; Medical research ; Metastasis ; NEIL3 ; p53 Protein ; Pathology ; Polymerase chain reaction ; Primary Research ; Prognosis ; Prognostic signature ; Proteins ; Real-time quantitative PCR ; Regression analysis ; Signal transduction ; Software ; Therapeutic targets ; Tumor-infiltrating lymphocytes ; Values ; Western blotting</subject><ispartof>Cancer cell international, 2021-04, Vol.21 (1), p.228-228, Article 228</ispartof><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c597t-319977871a6941f172e944dc79091bfe3903d588005e94ba6a5a8abc2c75885f3</citedby><cites>FETCH-LOGICAL-c597t-319977871a6941f172e944dc79091bfe3903d588005e94ba6a5a8abc2c75885f3</cites><orcidid>0000-0003-2315-4822</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059184/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2528916065?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33879165$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Cui</creatorcontrib><creatorcontrib>Liu, Jian</creatorcontrib><creatorcontrib>Zhou, Haomiao</creatorcontrib><creatorcontrib>Qian, Xin</creatorcontrib><creatorcontrib>Sun, Hui</creatorcontrib><creatorcontrib>Chen, Xuewen</creatorcontrib><creatorcontrib>Zheng, Miaosen</creatorcontrib><creatorcontrib>Bian, Tingting</creatorcontrib><creatorcontrib>Liu, Lei</creatorcontrib><creatorcontrib>Liu, Yifei</creatorcontrib><creatorcontrib>Zhang, Jianguo</creatorcontrib><title>NEIL3 may act as a potential prognostic biomarker for lung adenocarcinoma</title><title>Cancer cell international</title><addtitle>Cancer Cell Int</addtitle><description>Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death. This study aimed to develop and validate reliable prognostic biomarkers and signature.
Differentially expressed genes were identified based on three Gene Expression Omnibus (GEO) datasets. Based on 1052 samples' data from our cohort, GEO and The Cancer Genome Atlas, we explored the relationship of clinicopathological features and NEIL3 expression to determine clinical effect of NEIL3 in LUAD. Western blotting (22 pairs of tumor and normal tissues), Real-time quantitative PCR (19 pairs of tumor and normal tissues), and immunohistochemical analyses (406-tumor tissues subjected to microarray) were conducted. TIMER and ImmuCellAI analyzed relationship between NEIL3 expression and the abundance of tumor-infiltrating immune cells in LUAD. The co-expressed-gene prognostic signature was established based on the Cox regression analysis.
This study identified 502 common differentially expressed genes and confirmed that NEIL3 was significantly overexpressed in LUAD samples (P < 0.001). Increased NEIL3 expression was related to advanced stage, larger tumor size and poor overall survival (p < 0.001) in three LUAD cohorts. The proportions of natural T regulatory cells and induced T regulatory cells increased in the high NEIL3 group, whereas those of B cells, Th17 cells and dendritic cells decreased. Gene set enrichment analysis indicated that NEIL3 may activate cell cycle progression and P53 signaling pathway, leading to poor outcomes. We identified nine prognosis-associated hub genes among 370 genes co-expressed with NEIL3. A 10-gene prognostic signature including NEIL3 and nine key co-expressed genes was constructed. Higher risk-score was correlated with more advanced stage, larger tumor size and worse outcome (p < 0.05). Finally, the signature was verified in test cohort (GSE50081) with superior diagnostic accuracy.
This study suggested that NEIL3 has the potential to be an immune-related therapeutic target and an independent predictor of LUAD prognosis. We also developed a prognostic signature for LUAD with a precise diagnostic accuracy.</description><subject>Adenocarcinoma</subject><subject>Bioinformatics</subject><subject>Biomarkers</subject><subject>Cell cycle</subject><subject>Dendritic cells</subject><subject>DNA microarrays</subject><subject>Gene expression</subject><subject>Gene set enrichment analysis</subject><subject>Genomes</subject><subject>Helper cells</subject><subject>Immunohistochemistry</subject><subject>Immunoregulation</subject><subject>Lung adenocarcinoma</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>NEIL3</subject><subject>p53 Protein</subject><subject>Pathology</subject><subject>Polymerase chain reaction</subject><subject>Primary Research</subject><subject>Prognosis</subject><subject>Prognostic signature</subject><subject>Proteins</subject><subject>Real-time quantitative PCR</subject><subject>Regression analysis</subject><subject>Signal transduction</subject><subject>Software</subject><subject>Therapeutic targets</subject><subject>Tumor-infiltrating lymphocytes</subject><subject>Values</subject><subject>Western blotting</subject><issn>1475-2867</issn><issn>1475-2867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkU9v1DAQxS0EoqXwBTggS1y4hHrs-N8FCVUFVlqVS3u2Jo69ZMnGi51U6rfH2y1Vy8nWzJuf3swj5D2wzwBGnRfgVsiGcWgYWGGa9gU5hVbLhhulXz75n5A3pWwZA20Ue01OhDDagpKnZHV1uVoLusM7in6mWCjSfZrDNA840n1OmymVefC0G9IO8--QaUyZjsu0odiHKXnMfphq7y15FXEs4d3De0Zuvl1eX_xo1j-_ry6-rhsvrZ4bAdZqbTSgsi1E0DzYtu29tsxCF4OwTPTSGMZkbXSoUKLBznOva1VGcUZWR26fcOv2eai27lzCwd0XUt44zNXxGJzv65zqFffKtCil0RxYjzFG1nIZ2sr6cmTtl24Xel_Xzjg-gz7vTMMvt0m3zjBpwRwAnx4AOf1ZQpndbig-jCNOIS3FcQmKc6E0q9KP_0m3aclTPVVVcVPjYEpWFT-qfE6l5BAfzQBzh9TdMXVXU3f3qbuDiw9P13gc-Rez-AsydabG</recordid><startdate>20210420</startdate><enddate>20210420</enddate><creator>Zhao, Cui</creator><creator>Liu, Jian</creator><creator>Zhou, Haomiao</creator><creator>Qian, Xin</creator><creator>Sun, Hui</creator><creator>Chen, Xuewen</creator><creator>Zheng, Miaosen</creator><creator>Bian, Tingting</creator><creator>Liu, Lei</creator><creator>Liu, Yifei</creator><creator>Zhang, Jianguo</creator><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2315-4822</orcidid></search><sort><creationdate>20210420</creationdate><title>NEIL3 may act as a potential prognostic biomarker for lung adenocarcinoma</title><author>Zhao, Cui ; Liu, Jian ; Zhou, Haomiao ; Qian, Xin ; Sun, Hui ; Chen, Xuewen ; Zheng, Miaosen ; Bian, Tingting ; Liu, Lei ; Liu, Yifei ; Zhang, Jianguo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c597t-319977871a6941f172e944dc79091bfe3903d588005e94ba6a5a8abc2c75885f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma</topic><topic>Bioinformatics</topic><topic>Biomarkers</topic><topic>Cell cycle</topic><topic>Dendritic cells</topic><topic>DNA microarrays</topic><topic>Gene expression</topic><topic>Gene set enrichment analysis</topic><topic>Genomes</topic><topic>Helper cells</topic><topic>Immunohistochemistry</topic><topic>Immunoregulation</topic><topic>Lung adenocarcinoma</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>NEIL3</topic><topic>p53 Protein</topic><topic>Pathology</topic><topic>Polymerase chain reaction</topic><topic>Primary Research</topic><topic>Prognosis</topic><topic>Prognostic signature</topic><topic>Proteins</topic><topic>Real-time quantitative PCR</topic><topic>Regression analysis</topic><topic>Signal transduction</topic><topic>Software</topic><topic>Therapeutic targets</topic><topic>Tumor-infiltrating lymphocytes</topic><topic>Values</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Cui</creatorcontrib><creatorcontrib>Liu, Jian</creatorcontrib><creatorcontrib>Zhou, Haomiao</creatorcontrib><creatorcontrib>Qian, Xin</creatorcontrib><creatorcontrib>Sun, Hui</creatorcontrib><creatorcontrib>Chen, Xuewen</creatorcontrib><creatorcontrib>Zheng, Miaosen</creatorcontrib><creatorcontrib>Bian, Tingting</creatorcontrib><creatorcontrib>Liu, Lei</creatorcontrib><creatorcontrib>Liu, Yifei</creatorcontrib><creatorcontrib>Zhang, Jianguo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cancer cell international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Cui</au><au>Liu, Jian</au><au>Zhou, Haomiao</au><au>Qian, Xin</au><au>Sun, Hui</au><au>Chen, Xuewen</au><au>Zheng, Miaosen</au><au>Bian, Tingting</au><au>Liu, Lei</au><au>Liu, Yifei</au><au>Zhang, Jianguo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NEIL3 may act as a potential prognostic biomarker for lung adenocarcinoma</atitle><jtitle>Cancer cell international</jtitle><addtitle>Cancer Cell Int</addtitle><date>2021-04-20</date><risdate>2021</risdate><volume>21</volume><issue>1</issue><spage>228</spage><epage>228</epage><pages>228-228</pages><artnum>228</artnum><issn>1475-2867</issn><eissn>1475-2867</eissn><abstract>Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death. This study aimed to develop and validate reliable prognostic biomarkers and signature.
Differentially expressed genes were identified based on three Gene Expression Omnibus (GEO) datasets. Based on 1052 samples' data from our cohort, GEO and The Cancer Genome Atlas, we explored the relationship of clinicopathological features and NEIL3 expression to determine clinical effect of NEIL3 in LUAD. Western blotting (22 pairs of tumor and normal tissues), Real-time quantitative PCR (19 pairs of tumor and normal tissues), and immunohistochemical analyses (406-tumor tissues subjected to microarray) were conducted. TIMER and ImmuCellAI analyzed relationship between NEIL3 expression and the abundance of tumor-infiltrating immune cells in LUAD. The co-expressed-gene prognostic signature was established based on the Cox regression analysis.
This study identified 502 common differentially expressed genes and confirmed that NEIL3 was significantly overexpressed in LUAD samples (P < 0.001). Increased NEIL3 expression was related to advanced stage, larger tumor size and poor overall survival (p < 0.001) in three LUAD cohorts. The proportions of natural T regulatory cells and induced T regulatory cells increased in the high NEIL3 group, whereas those of B cells, Th17 cells and dendritic cells decreased. Gene set enrichment analysis indicated that NEIL3 may activate cell cycle progression and P53 signaling pathway, leading to poor outcomes. We identified nine prognosis-associated hub genes among 370 genes co-expressed with NEIL3. A 10-gene prognostic signature including NEIL3 and nine key co-expressed genes was constructed. Higher risk-score was correlated with more advanced stage, larger tumor size and worse outcome (p < 0.05). Finally, the signature was verified in test cohort (GSE50081) with superior diagnostic accuracy.
This study suggested that NEIL3 has the potential to be an immune-related therapeutic target and an independent predictor of LUAD prognosis. We also developed a prognostic signature for LUAD with a precise diagnostic accuracy.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>33879165</pmid><doi>10.1186/s12935-021-01938-4</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-2315-4822</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1475-2867 |
| ispartof | Cancer cell international, 2021-04, Vol.21 (1), p.228-228, Article 228 |
| issn | 1475-2867 1475-2867 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_cdbc26d62c684a5587210dafff0425e4 |
| source | Publicly Available Content (ProQuest); PubMed Central |
| subjects | Adenocarcinoma Bioinformatics Biomarkers Cell cycle Dendritic cells DNA microarrays Gene expression Gene set enrichment analysis Genomes Helper cells Immunohistochemistry Immunoregulation Lung adenocarcinoma Lung cancer Lymphatic system Lymphocytes B Lymphocytes T Medical prognosis Medical research Metastasis NEIL3 p53 Protein Pathology Polymerase chain reaction Primary Research Prognosis Prognostic signature Proteins Real-time quantitative PCR Regression analysis Signal transduction Software Therapeutic targets Tumor-infiltrating lymphocytes Values Western blotting |
| title | NEIL3 may act as a potential prognostic biomarker for lung adenocarcinoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A37%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NEIL3%20may%20act%20as%20a%20potential%20prognostic%20biomarker%20for%20lung%20adenocarcinoma&rft.jtitle=Cancer%20cell%20international&rft.au=Zhao,%20Cui&rft.date=2021-04-20&rft.volume=21&rft.issue=1&rft.spage=228&rft.epage=228&rft.pages=228-228&rft.artnum=228&rft.issn=1475-2867&rft.eissn=1475-2867&rft_id=info:doi/10.1186/s12935-021-01938-4&rft_dat=%3Cproquest_doaj_%3E2516223670%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c597t-319977871a6941f172e944dc79091bfe3903d588005e94ba6a5a8abc2c75885f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2528916065&rft_id=info:pmid/33879165&rfr_iscdi=true |